Dr. Michael Houghton Wins 2020 Nobel Prize

University of Alberta virologist awarded Nobel Prize

Michael Houghton won the 2020 Nobel Prize in Physiology or Medicine along with Harvey J. Alter and Charles M. Rice for the discovery of the hepatitis C virus (HCV).

Read story

Research , Health And Wellness , Business , Science and Technology

New provincial research funding for U of A aims to create made-in-Alberta vaccine and drug development pipeline

Government of Alberta makes $55.1-million investment to take new vaccines and antiviral drugs from discovery to manufacturing.

01 December 2021 By Gillian Rutherford

Research , Business , Science and Technology , Health And Wellness

U of A-industry partnership poised to close Canada’s drug supply gaps

The Canadian Critical Drug Initiative aims to transform Alberta into a powerhouse in the development of life-saving therapies.

02 November 2021 By Niall McKenna

Research , Business , Science and Technology , Health And Wellness

A Nobel Search

What does it take to win the world’s top prize in medicine? Inside Michael Houghton’s seven-year hunt for a mystery virus

24 May 2021 By Bruce Grierson

Background

In 1989, Michael Houghton discovered the virus now known as hepatitis C with his colleagues Qui-Lim Choo and George Kuo. Because of their discovery, new screening tests were developed for blood donations, and by 1992, the virus was virtually eliminated from blood supplies. By 1996, this screening led to an annual reduction in new hep C infections by more than 80 per cent.

The hepatitis C virus is very virulent. It can lead to cirrhosis, end-stage liver disease, and liver cancer for people who carry the virus. To prevent the spread of hepatitis C, the world urgently needs a vaccine. In 2012, Houghton and his team here at the University of Alberta developed a vaccine that is now in late pre-clinical stage testing. Based on the discovery of the virus, antiviral therapies have also been developed that will cure 95 per cent of carriers. This is the first chronic viral illness that can be cured.

Since the outbreak, Dr. Houghton is leading an effort to produce a COVID-19 vaccine. He was successful in creating a vaccine for SARS-CoV-1 in 2004; however, this vaccine was never needed as the original SARS disappeared.

Dr. Houghton was appointed a full professor in the Department of Medical Microbiology and Immunology in the U of A Faculty of Medicine & Dentistry on June 1, 2010. His lab is in the Li Ka Shing Institute of Virology, which was created in 2010 through a gift of $25 million from the Li Ka Shing (Canada) Foundation as well as a commitment of $52.5 million from the Government of Alberta.

Related News

The Potential in Alberta’s Life Sciences Sector

03 February 2022

Nobel-prize recipient Michael Houghton discusses the life sciences sector in Alberta and the great potential it holds to become a key driver of the Canadian economy.

One Year Later: Michael Houghton Reflects on His Nobel Prize Win

Mike Brown
09 December 2021

Dr. Michael Houghton reflects on his life and work since being recognized globally for his research and discovery of the Hepatitis C virus.

What Has a Nobel Prize Ever Done For You?

Kate Black
06 December 2021

Turns out having all-star scientists on board draws students, researchers and funding that boost the economy

How to build an ‘it’ team to take on the world’s deadliest viruses

Gillian Rutherford
08 December 2020

It’s no accident that the University of Alberta is home to so many top virologists.

Going Viral

Gillian Rutherford
07 December 2020

A timeline of milestones and discoveries showing how the U of A built a Canadian centre of excellence in virology research

Passion and Perseverance: What a Trainee Learned from Nobel Prize-Winner Michael Houghton

07 December 2020

Houghton attributes his success to teamwork, to following his passion for solving disease, and persistence. To me, the main lesson I took away from his talk is: follow your passion and persevere, you are on the right path!

A Student’s Reflections on Michael Houghton’s 2020 Nobel Prize in Physiology or Medicine

01 December 2020

"Having interned in a virology research group only one building away from Dr. Michael Houghton’s office on the seventh floor of the Li Ka Shing Centre for Health Research Innovation, I have a first-hand understanding of the passion and commitment needed to excel in academic research."

U of A Nobel winner’s impact extends from personal to global

Gillian Rutherford
08 October 2020

Michael Houghton’s colleagues and trainees describe the determination that led him to discover the hepatitis C virus and continue his quest for vaccines that will save millions of lives.

COVID-19 has ‘created a new paradigm for developing vaccines,’ says U of A Nobel winner

Michael Brown
08 October 2020

A vaccine against SARS-CoV-2 is essential—and thanks to scientific advances and global will, it will likely come faster than any previous vaccine, according to virologist Michael Houghton.

How the U of A's Li Ka Shing Institute of Virology is responding to the COVID-19 crisis

Gillian Rutherford
23 March 2020

Institute was designed for rapid response to viral pandemic.

Leading researchers team up to bring promising chemotherapy treatment to human trials

Michael Brown
22 November 2021

After a rejected patent application nearly derailed years of research, the new drug is now in clinical trials thanks to timely support from two top experts.

Medical research leads U of A performance in latest U.S. News ranking of world’s best universities

Michael Brown
03 November 2021

Food science, agriculture, engineering and natural science also among 18 U of A subjects ranked in world’s top 100.

Hepatitis C vaccine could be available within five years, says U of A Nobel laureate Michael Houghton

Michael Brown
12 July 2021

New vaccine has potential to save hundreds of thousands of lives each year and dramatically reduce cost of treating infections with antiviral drugs.

Lessons learned from Nobel winner Michael Houghton drive innovation for pharmacy researcher

Gillian Rutherford
21 January 2021

For Khaled Barakat, a focus on teamwork and patient needs has led to breakthroughs in the search for cancer therapies, antivirals and safer drugs.

Michael Houghton’s Nobel Prize win shows Canada’s strength in biotechnology

Bill Flanagan, President, University of Alberta
14 December 2020

U of A president Bill Flanagan says virologist Michael Houghton's Nobel Prize sets the stage for Canada to play an even larger role in vaccine and therapeutic research, development and production.

U of A’s Li Ka Shing Applied Virology Institute receives $20 million in new funding from Government of Alberta

Michael Brown
11 December 2020

Research hub headed by Nobel laureate Michael Houghton gains significant provincial support to accelerate research and commercialization of antiviral drugs and vaccines.

Michael Houghton’s Nobel Prize win inspires researchers to ask the big questions

Gillian Rutherford
09 December 2020

His colleagues at the University of Alberta talk about the power of collaboration to help fight viruses that plague the world.

Nobel Lecture: Michael Houghton, Nobel Prize in Physiology or Medicine 2020

08 December 2020

Michael Houghton delivered his Nobel Lecture on 7 December 2020. He was introduced by Professor Maria Masucci.